CITY OF TSHWANE, South Africa– In response to growing demand throughout Sub-Saharan Africa, Cytespace Africa Laboratories (Cytespace), an MLM Medical Labs company and the only central laboratory in South Africa with full CAP accreditation, has greatly increased the scope of its molecular testing capabilities. Cytespace has increased its molecular diagnostic capacity with the installation of several Roche Cobas® 5800 systems, allowing for high-volume, fully automated PCR testing to support an expanding portfolio of clinical trials in infectious illness and other areas.
The laboratory’s ability to help sponsors conducting vaccine and treatment trials for high-burden diseases like HIV, Hepatitis B and C, STIs, and newly developing respiratory or transplant-related infections is improved by this calculated expansion.
Using a one-roof concept, Cytespace combines clinical chemistry, hematology, flow cytometry, molecular diagnostics, and a Biosafety Level 3 (BSL-3) laboratory. In order to ensure centralized monitoring and quicker research initiation, the site also handles all kit construction and logistics, including both inbound and outward sample handling.
Cytespace’s position as Africa’s go-to clinical trial laboratory partner is further enhanced by this investment. With the support of MLM Medical Labs’ worldwide specialist lab infrastructure and complete adherence to CAP and ISO 15189 standards, Cytespace provides:
- Rapid, high-throughput diagnosis of infectious diseases
- Global alignment and harmonization of testing procedures
- Complete adherence to regulations and strong data integrity
- Complete kit logistics and sample monitoring from one location
“As global sponsors increasingly turn to South Africa for clinical research, we are proud to invest in localized capabilities that reduce complexity, cost, and time to data,”stated MLM Medical Labs CEO Scott Houlton.
“Cytespace Africa Laboratories is well-positioned to support scalable trial operations across high-priority therapeutic areas—providing faster startup, fewer shipment delays, and stronger regional oversight.”
